ESPR

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Days

Hours

Mins

Sec

Claim Now

Peers: SUPN ALKS PRGO BHC AMRX INDV LNTH TEVA VTRS HRMY

| Held by: VTI IWM FESM VXF XPH IWN VTWO IWO IWC VHT

Scroll to Statements

Index	RUT
Market Cap	814.31M
Enterprise Value	1.20B
Income	-7.42M
Sales	418.24M
Book/sh	-1.20
Cash/sh	0.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	294
IPO	Jun 26, 2013

P/E	-
Forward P/E	11.63
PEG	-
P/S	1.95
P/B	-
P/C	5.21
P/FCF	-
EV/EBITDA	15.84
EV/Sales	2.87
Quick Ratio	1.18
Current Ratio	1.53
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.10
EPS next Y	0.27
EPS next Q	-0.00
EPS this Y	63.64%
EPS next Y	779.17%
EPS next 5Y	-
EPS past 3/5Y	68.58% 53.87%
Sales past 3/5Y	74.80% 12.12%
EPS Y/Y TTM	92.51%
Sales Y/Y TTM	61.13%
EPS Q/Q	51.43%
Sales Q/Q	23.25%
Earnings	May 08 BMO
EPS/Sales Surpr.	-169.54% -5.23%

Insider Own	6.08%
Insider Trans	-0.73%
Inst Own	72.04%
Inst Trans	9.26%
ROA	-1.89%
ROE	-
ROIC	-4.84%
Gross Margin	68.38%
Oper. Margin	18.12%
Profit Margin	-1.77%
SMA20	0.25%
SMA50	6.38%
SMA200	3.86%
Trades

Shs Outstand	257.40M
Shs Float	242.03M
Short Float	8.56%
Short Ratio	1.57
Short Interest	20.72M
52W High	4.18 -24.31%
52W Low	1.00 216.00%
Volatility	0.57% 0.51%
ATR (14)	0.03
RSI (14)	64.24
Beta	1.09
Rel Volume	0.60
Avg Volume	13.19M
Volume	7,866,010

Perf Week	0.32%
Perf Month	0.64%
Perf Quarter	21.07%
Perf Half Y	-14.36%
Perf YTD	-14.59%
Perf Year	174.78%
Perf 3Y	127.34%
Perf 5Y	-84.58%
Perf 10Y	-69.47%
Recom	3.14
Target Price	3.19
Prev Close	3.16
Price	3.16
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-25-25	Initiated	Piper Sandler	Overweight	$9
Dec-18-24	Initiated	Goldman	Neutral	$4
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$8
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform	$2.50
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11

Show Previous Ratings

Jun-18-26 11:29AM	Are GBTG, BGMS, SUNE, ESPR Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-26-26 08:00AM	Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 (GlobeNewswire)
May-14-26 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-26 08:00AM	Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 (GlobeNewswire)
May-04-26 02:53PM	Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? (PR Newswire)
11:13AM	Loading…
May-01-26 11:13AM	ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal (Quartz) +55.50%
08:28AM	Summits self-inflicted stumble; Esperions take-private deal (BioPharma Dive)
07:00AM	Esperion to be Acquired by ARCHIMED (GlobeNewswire)
Apr-23-26 08:00AM	Esperion to Report First Quarter 2026 Financial Results on May 7 (GlobeNewswire)
Apr-02-26 04:00PM	Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) (GlobeNewswire)
Mar-31-26 08:00AM	Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 08:00AM	Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 (GlobeNewswire)
Mar-17-26 08:00AM	Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session (GlobeNewswire)
Mar-16-26 06:30AM	Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia (GlobeNewswire) +10.25%
Mar-10-26 03:00PM	Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -11.18%
07:10AM	Loading…
07:10AM	Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
06:14AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-26 08:20AM	MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-04-26 10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
10:00AM	electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
06:11AM	Esperion to acquire Corstasis for cardiovascular franchise expansion (Pharmaceutical Technology)
05:39AM	Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements (Insider Monkey)
Mar-03-26 08:25AM	Esperion Acquires Enbumyst Maker Corstasis (Benzinga) -11.01%
06:00AM	Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) (Business Wire)
Feb-24-26 10:00AM	Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 (GlobeNewswire)
Feb-18-26 08:00AM	Esperion to Participate in The 2026 Citizens Life Sciences Conference (GlobeNewswire)
Feb-17-26 08:00AM	Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 (GlobeNewswire)
Feb-11-26 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:00PM	Loading…
Jan-11-26 06:00PM	Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:00AM	Esperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes (GlobeNewswire)
Dec-09-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-25 08:00AM	Esperion Partner Otsuka Launches NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-19-25 08:00AM	Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-18-25 07:00AM	Esperion Partner HLS Therapeutics Announces Approval of NILEMDO for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease (GlobeNewswire)
Nov-10-25 08:00AM	Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 (GlobeNewswire) +8.27%
Nov-07-25 11:22AM	ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down (Zacks) +6.40%
Nov-06-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -14.97%
02:06PM	Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 08:00AM	Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer (GlobeNewswire)
Nov-03-25 08:00AM	Esperion to Participate in Jefferies Global Healthcare Conference - London (GlobeNewswire)
Oct-28-25 08:00AM	Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. (GlobeNewswire)
Oct-27-25 08:00AM	Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire) +7.01%
Oct-23-25 08:00AM	Esperion to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Oct-17-25 11:52AM	ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up (Zacks)
Oct-16-25 08:00AM	Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis (GlobeNewswire) +5.16%
Oct-10-25 01:01AM	ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play (MoneyShow)
Oct-09-25 08:57AM	ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering (Zacks)
Oct-07-25 09:29PM	Esperion Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -16.83%
04:01PM	Esperion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks) -5.45%
Oct-03-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Prior to April 19, 2040 (GlobeNewswire) +13.79%
Sep-24-25 06:40AM	Oritain expands traceability offer to leather (Just Style)
Sep-19-25 08:00AM	Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL in Japan for the Treatment of Hypercholesterolemia (GlobeNewswire)
Aug-29-25 08:00AM	Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias (GlobeNewswire)
Aug-26-25 08:00AM	Esperion to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-22-25 03:11PM	Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock? (Zacks)
Aug-14-25 06:31AM	HLS Therapeutics Announces Q2 2025 Financial Results (PR Newswire) +6.70%
Aug-07-25 05:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.73%
Aug-06-25 11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks) +18.52%
Aug-05-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.72%
06:14AM	Esperion Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 05:10PM	Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-29-25 10:00AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) -7.55%
09:34AM	Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors (Insider Monkey)
Jul-22-25 08:00AM	Esperion to Report Second Quarter 2025 Financial Results on August 5 (GlobeNewswire) +6.09%
Jul-17-25 07:00AM	Whats the Status on Digital Product Passport Implementation? (Sourcing Journal) +10.71%
Jul-08-25 08:00AM	Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +5.41%
Jul-01-25 08:06AM	Esperion Appoints Craig Thompson to Board of Directors (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-02-25 08:00AM	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +8.10%
May-20-25 08:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.19%
May-12-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire)
May-09-25 09:55AM	HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines (Pharmaceutical Technology) -10.60%
08:00AM	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:32AM	HLS Therapeutics Announces Q1 2025 Financial Results (PR Newswire)
06:30AM	HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada (PR Newswire)
06:30AM	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada (GlobeNewswire)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) -10.72%
03:05AM	Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.10%
06:10AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.80%
Apr-25-25 08:00AM	Esperion to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -7.15%
08:00AM	Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 (GlobeNewswire)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:00AM	Esperion to Report First Quarter 2025 Financial Results on May 6 (GlobeNewswire)
Apr-22-25 09:35AM	Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +9.12%
Apr-21-25 05:32PM	Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.32%

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

PresidentMr. Sheldon L. Koenig M.B.A.

Chief Financial OfficerMr. Benjamin Halladay M.B.A.

Chief Commercial OfficerMr. John B. Harlow Jr.

Chief Technical Operations OfficerMr. Glenn P. Brame

Chief Legal & Corporate Affairs OfficerMr. Benjamin O. Looker J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Looker Benjamin	Chief Legal Officer	Jun 17 '26	Sale	3.15	11,824	37,305	667,524	Jun 18 04:06 PM
Koenig Sheldon L.	President and CEO	Jun 17 '26	Sale	3.15	53,588	169,070	2,119,111	Jun 18 04:06 PM
Halladay Benjamin	Chief Financial Officer	Jun 17 '26	Sale	3.15	10,773	33,989	702,829	Jun 18 04:05 PM
Koenig Sheldon L.	Officer	Jun 17 '26	Proposed Sale	3.15	53,588	169,059		Jun 17 03:34 PM
Halladay Benjamin	Officer	Jun 17 '26	Proposed Sale	3.15	10,773	33,986		Jun 17 03:23 PM
Looker Benjamin	Officer	Jun 17 '26	Proposed Sale	3.15	11,824	37,301		Jun 17 03:11 PM
Looker Benjamin	Chief Legal Officer	Mar 17 '26	Sale	2.70	5,708	15,429	679,348	Mar 18 04:13 PM
Koenig Sheldon L.	President and CEO	Mar 17 '26	Sale	2.72	25,578	69,547	2,172,699	Mar 18 04:13 PM
Halladay Benjamin	Chief Financial Officer	Mar 17 '26	Sale	2.71	6,424	17,377	713,602	Mar 18 04:12 PM
Halladay Benjamin	Officer	Mar 17 '26	Proposed Sale	2.70	6,424	17,375		Mar 17 03:19 PM
Looker Benjamin	Officer	Mar 17 '26	Proposed Sale	2.70	5,708	15,428		Mar 17 03:17 PM
Koenig Sheldon L.	Officer	Mar 17 '26	Proposed Sale	2.72	25,578	69,552		Mar 17 03:12 PM
Looker Benjamin	General Counsel	Jan 20 '26	Sale	2.88	1,689	4,868	384,216	Jan 21 05:17 PM
Looker Benjamin	Officer	Jan 20 '26	Proposed Sale	2.88	1,689	4,867		Jan 20 03:14 PM
Koenig Sheldon L.	President and CEO	Dec 17 '25	Sale	3.67	48,244	177,200	1,470,587	Dec 18 04:10 PM
Halladay Benjamin	Chief Financial Officer	Dec 17 '25	Sale	3.67	7,337	26,905	467,525	Dec 18 04:09 PM
Looker Benjamin	General Counsel	Dec 17 '25	Sale	3.67	6,517	23,898	385,905	Dec 18 04:09 PM
Koenig Sheldon L.	Officer	Dec 17 '25	Proposed Sale	3.67	48,244	177,200		Dec 17 03:52 PM
Looker Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	6,517	23,897		Dec 17 03:26 PM
Halladay Benjamin	Officer	Dec 17 '25	Proposed Sale	3.67	7,337	26,906		Dec 17 03:18 PM
Looker Benjamin	Officer	Oct 17 '25	Proposed Sale	2.62	1,248	3,275		Oct 17 03:13 PM
Looker Benjamin	General Counsel	Sep 17 '25	Sale	2.80	6,267	17,573	393,670	Sep 18 04:06 PM
Koenig Sheldon L.	President and CEO	Sep 17 '25	Sale	2.79	28,427	79,254	1,518,831	Sep 18 04:06 PM
Halladay Benjamin	Chief Financial Officer	Sep 17 '25	Sale	2.81	7,046	19,785	474,862	Sep 18 04:06 PM
Koenig Sheldon L.	Officer	Sep 17 '25	Proposed Sale	2.79	28,427	79,240		Sep 17 03:37 PM
Halladay Benjamin	Officer	Sep 17 '25	Proposed Sale	2.81	7,046	19,789		Sep 17 03:30 PM
Looker Benjamin	Officer	Sep 17 '25	Proposed Sale	2.80	6,267	17,576		Sep 17 03:25 PM
Looker Benjamin	General Counsel	Jul 17 '25	Sale	1.13	1,304	1,470	399,937	Jul 18 04:07 PM
Halladay Benjamin	Chief Financial Officer	Jul 17 '25	Sale	1.11	11	12	474,462	Jul 18 04:05 PM
Looker Benjamin	Officer	Jul 17 '25	Proposed Sale	1.13	1,304	1,469		Jul 17 05:09 PM
Halladay Benjamin	Officer	Jul 17 '25	Proposed Sale	1.12	11	12		Jul 17 03:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Esperion Therapeutics Inc

Upgrade your Finviz experience